Patent, Trademark & Copyright Journal® Index-Summary

PATENT AND TRADEMARK OFFICE (PTO)

– Applications

– Appointments

– – Deputy director Barner resigns, 81:250
– – Trademark Comm'r Beresford retires, Cohn will succeed, 81:64

– Appropriations

– – FY2011 budget request approved by House panel, 80:323; for further action, see LEGISLATION, FEDERAL, HR 3082
– – Innovation and job creation, PTO role discussed at House panel hearing, 81:369
– – Obama asks Congress to allow PTO to spend all collected fees, 80:323; business groups support request, 80:414
– – Supplemental appropriations bill

See LEGISLATION, FEDERAL, HR 5874

– – Underfunding of PTO criticized by Judge Michel, 80:145; Michel urges increased funding, 80:414

– Awards, Natl. Medal of Technology and Innovation, nominations committee, 80:134; nominations for awards sought, 81:300
– Bilateral cooperation agreements signed

– – Chinese IP Office, 80:132
– – Russian IP Office, 80:209

– Communications tools

– – Electronic public data, PTO to provide free access through Google, 80:154
– – Facebook page launched, 80:132
– – Subscriptions, online center launched, 81:264
– – Twitter account added, 81:92

– Fees

– – Authority to set fees and diversion of fees

– – – Hill Watch, status of pending bills, 80:614
– – – House Judiciary Comm. hearing, 80:5
– – – Legislation

See LEGISLATION, FEDERAL, HR 3081, HR 5322

– – Obama asks Congress to allow PTO to spend all collected fees, 80:323; business groups support request, 80:414
– – Patent Prosecution Highway, application fees ended, 80:126

– General Counsel Office, mailing address change, 80:301
– Humanitarian needs, pilot program to incentivize technology to address, comment sought, 80:686; comments received, 81:143
– Legislative activity table, May 21, 80:106; June 4, 80:170; July 23, 80:390; Aug. 20, 80:547; Nov. 19, 81:93; Nov. 26, 81:121; Dec. 17, 81:233
– Maintenance filings for trademarks, amended rules issued, 80:302
– Manual of Examining Procedure for patents and trademarks, websites available for public comments, 81:350
– Patent classification systems, EPO and PTO agree to harmonize, 80:838
– Patent Examiner training program, public participation sought, 80:693
– Performance of patent examiners, GAO report describes, 80:733
– Performance Review Board, appointments announced, 80:829
– Public patent application review, PTO restarts program, 80:822
– Quality of examinations, measurement procedure changes announced, 80:785
– Racial and sex discrimination claims of PTO workers (U.S., rev sought), 81:299
– Regional offices

– – Expansion to depressed areas, Commissioner of Patents discusses, 80:691
– – Satellite office to open in Detroit, 81:248

– Reorganization, Kappos announces, 80:753
– Rulemaking, agency developments table, June 18, 80:246; June 25, 80:270; July 2, 80:304; July 23, 80:394
– Small businesses, study re impact of trademark bullying announced, 80:823
– Strategic Plan for 2010-2015, public comment sought, 80:333
– Telework options for PTO workers

See LEGISLATION, FEDERAL, HR 1722

– 2010-2011 review and outlook, Special Report, 81:384

PATENTABILITY

– Business method patents

– – Claims drafting after Bilski, AIPLA webinar, 80:576
– – Commodity sale risk management method is unpatentable, machine-or-transformation test is not sole tool (U.S., aff), 80:285; Analysis and Perspective, 80:307; Judge Michel's views on decision, 80:323; lawyers discuss decision, 80:423
– – Impact of Bilski decision discussed by conference speaker, 80:192
– – Instability after Bilski decision, conferees discuss, 81:376
– – IPO conferees discuss Bilski, 80:682
– – Post-Bilski world, predictions made by conferees, 80:88
– – Section 101 issues, conferees discuss, 80:726
– – 2010 business method partnership meeting, PTO hosts, BNA Insights, 80:740
– – Unresolved issues in Bilski decision, BNA Insights, 81:185

– Drug dosage calibration method is patentable (U.S., vac and rem), 80:288; supplemental briefs sought (Fed. Cir.), 80:681; claims are patent eligible, 81:244; lawyers analyze decision, 81:246
– Eligible subject matter after Bilski decision, PTO interim guidance, 80:416; text, 80:440
– Ex parte reexamination, PTO review of new question of patentability, 80:301
– Expert testimony on patentability fails to show attorney's malpractice harmed client (U.S., rev sought), 80:212; (rev den), 80:751
– Gene patents

– – Biotech experts discuss, 80:759
– – BNA Insights, 80:273
– – Cancer treatment gene patents, recusal of Judge Rader sought in Myriad case (Fed. Cir.), 80:371; amicus brief filed, 80:499; briefs filed, 81:10; reaction to DOJ amicus brief, 81:14; briefs filed, 81:210; Myriad reply brief filed, 81:277
– – Conferees discuss, 80:47
– – Impact of Myriad decision, BNA Insights, 80:583

– On-sale bar

See ON-SALE BAR

– Software

– – European Patent Office, Enlarged Board of Appeal rulings, 80:232; BNA webinar set, 81:318; contrasts with UK discussed, 81:375
– – Halftoning digital imaging process claims, abstractness not manifestly exhibited (Fed. Cir.), 81:171

– Tax strategy patents

– – Ban sought by groups, 80:760
– – Legislation to ban

See LEGISLATION, FEDERAL, S *139

– 2010-2011 review and outlook, Special Report, 81:384

PATENTS

– Applications

See APPLICATIONS

– Business method patents

See BUSINESS METHOD PATENTS

– Claims

See CLAIMS

– Damages

See DAMAGES

– Doctrine of equivalents

See DOCTRINE OF EQUIVALENTS

– Inequitable conduct

See INEQUITABLE CONDUCT

– Infringement

See INFRINGEMENT

– Interferences

See INTERFERENCES

– Inventorship

See INVENTORSHIP

– Jurisdiction

See JURISDICTION

– Legislation

See LEGISLATION, FEDERAL

– Licensing

See LICENSING

– Marking

See MARKING REQUIREMENTS FOR PATENTS

– Obviousness

See OBVIOUSNESS

– On-sale bar

See ON-SALE BAR

– Ownership

See OWNERSHIP

– Patentability

See PATENTABILITY

– Reexamination

See REEXAMINATION OF PATENTS

– Validity

See VALIDITY

PHARMACEUTICALS

See also GENERIC DRUGS
– Antitrust

See ANTITRUST

– Assignment of ropivacaine patents not made prior to filing of infringement suit, plaintiff lacks standing (Fed. Cir.), 81:82
– Attention deficit hyperactivity disorder drug patent invalid for lack of enablement and utility (D.N.J.), 80:541
– Bayer drug compound patent denied, obviousness double-patenting (Can. Fed. Ct. App.), 81:27
– Bayh-Dole Act “march-in rights,” NIH declines to exercise in Fabrazyme drug case, 81:229
– Brazilian patent office

– – Leukemia drug patent term limited, 81:26
– – Viagra, patent expiration, 80:26

– Cancer drug method-of-use patent invalid for obviousness-type double-patenting (Fed. Cir.), 80:480; (rehear en banc den), 81:16
– Cancer treatment gene patents, recusal of Judge Rader sought in Myriad case (Fed. Cir.), 80:371; amicus brief filed, 80:499; briefs filed, 81:10; reaction to DOJ amicus brief, 81:14; briefs filed, 81:210; Myriad reply brief filed, 81:277
– Coating patent, obviousness rejection on reexamination improper (Fed. Cir.), 81:311
– Costs of drugs in developing countries

– – India, drug availability at affordable prices, proposals offered, 80:611
– – Purchasing and distribution barriers cited, 80:388

– Counterfeiting, enforcement incidents increased in 2009, 80:100
– Dosage calibration method is patentable subject matter (U.S., vac and rem), 80:288; supplemental briefs sought (Fed. Cir.), 80:681; claims are patent eligible, 81:244; lawyers analyze decision, 81:246
– Erectile dysfunction drug, joint inventorship not shown (U.S., rev sought), 80:751; (rev den), 81:382
– Homeopathic medicine, qui tam pleading requirement fulfilled (E.D. Cal.), 80:819
– Muscle relaxants, method patents for administering invalid (Fed. Cir.), 80:470
– Patent term extension

– – Antibiotic drug Levaquin, extension for FDA approval delay (Fed. Cir.), 80:55; BNA Insights, 80:135
– – Anticoagulant drug, term extended pending court ruling in suit challenging PTO denial of extension (E.D. Va.), 80:165; summary judgment for patentee, 80:500; government declines appeal, 80:788
– – FDA phased review of new animal drug applications may reduce term extensions (Fed. Cir.), 80:20
– – Infant respiratory distress drug Surfaxin, extension issued, 80:827
– – Metvixia skin treatment drug, extension for FDA approval delay (Fed. Cir.), 80:56; BNA Insights, 80:135
– – Parkinson's disease drug, Mirapex, double patenting divisional safe harbor applicable (Fed. Cir., rehear en banc den), 80:44

– Renal disease treatment patent, inequitable conduct (N.D. Ill.), 80:61
– Transparency of FDA review process, draft proposals issued, 80:129
– Weight-loss supplements, likelihood of confusion between “ForsLean” and “Forsthin” marks (3d Cir.), 80:377; (U.S., rev sought), 81:232; (rev den), 81:315
– Yasmin oral contraceptive patent invalid for obviousness (U.S., rev den), 80:104

PHOTOGRAPHS

– “Ansel Adams Lost Negatives,” venue based on website advertising accessible to forum residents (N.D. Cal.), 81:178
– Copyright registration

– – Compilations, individual creator's right to sue for infringement (S.D.N.Y.), 80:50; (D. Ariz.), 80:541
– – Electronic filing of applications, CO interim rule, 81:382

– “Hope” poster based on photo of President Obama, copyright infringement suit settled (S.D.N.Y.), 81:347
– Sculptor not required to search internet for infringing photos of his work (W.D. Wash.), 80:575
– Single-use cameras, importation of refurbished products, exhaustion of U.S. patent rights (Fed. Cir.), 80:196; (U.S., rev sought), 81:28; (rev den), 81:232

PREEMPTION

– Accused infringer claims over patentee letters to customers (N.D. Ill.), 80:166
– Counterfeiting, state law not preempted (Ill. App. Ct.), 80:515
– Event planning website, data scraping by competitor does not violate CFAA (E.D. Va.), 80:734
– Plagiarism detection services, college student claims preempted (E.D. Va.), 80:516
– Reality television program concept, breach of contract claim preempted by Copyright Act (9th Cir.), 80:204; (en banc rehear grant), 80:764
– Right of publicity, adult film star's claim preempted (9th Cir.), 80:538

PRIOR ART

– Public patent application review, PTO restarts program, 80:822

PROCEDURE

– Appeals

See APPEALS

– Cancellation proceedings

– – Motion for leave to amend petition (Fed. Cir.), 80:96
– – “RoyalSilk,” reopening of case based on excusable neglect (T.T.A.B.), 81:295

– Damages

See DAMAGES

– De novo judicial review, remand of obviousness ruling (U.S., rev sought), 80:660; (rev den), 80:751
– Declaratory judgments

See DECLARATORY JUDGMENTS

– Equitable estoppel, eyeglass frame patent infringement suit dismissed (Fed. Cir.), 80:161
– Evidence

See EVIDENCE

– Hatch-Waxman counterclaim cannot be used to challenge overbroad use code in Orange Book listing for brand name drug (Fed. Cir., rehear en banc den), 80:474; (U.S., rev sought), 81:314
– Inequitable conduct, case management strategies to reduce predatory pleadings, BNA Insights, 81:265
– Injunctions

See INJUNCTIONS

– ITC resolution of IP disputes, conferees discuss, 80:164
– Joinder of licensee and patent owner required in accused infringer's declaratory judgment suit (Fed. Cir.), 81:83
– Judges

See JUDGES

– Judicial estoppel, fraud assertion re adult entertainment company petition to cancel “Route 66” television program mark not barred (T.T.A.B.), 80:824
– Jurisdiction

See JURISDICTION

– Pleadings

– – Amended complaint of copyright infringement by The PJs animated television show (7th Cir.), 80:337
– – Online music sales, price fixing allegations against major labels stated actionable claim (U.S., rev sought), 80:660; (rev den), 81:315
– – Video signal synchronization patent, inducement and contributory infringement claims inadequately pleaded (E.D. Cal.), 81:21

– Preemption

See PREEMPTION

– Prosecution laches, Temodar cancer drug patent (Fed. Cir.), 81:77
– Res judicata

See RES JUDICATA

– Standing

See STANDING

– Summary judgments

– – Appeal of partial summary judgment not waived by stipulated final judgment (Fed. Cir.), 81:219
– – Cancellation suit not formally suspend by filing (T.T.A.B.), 80:824

– Trial management of patent cases, judge discusses, 81:61
– Venue

See VENUE

PTO

See PATENT AND TRADEMARK OFFICE (PTO)